Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group. Crowell TA, et al. Among authors: pagliuzza a. Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15. Lancet HIV. 2019. PMID: 31000477 Free PMC article. Clinical Trial.
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.
Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV411 study group. Colby DJ, et al. Among authors: pagliuzza a. Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11. Nat Med. 2018. PMID: 29892063 Free PMC article.
Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.
Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG. Scully EP, et al. Among authors: pagliuzza a. J Infect Dis. 2019 Mar 15;219(7):1084-1094. doi: 10.1093/infdis/jiy617. J Infect Dis. 2019. PMID: 30371873 Free PMC article.
Clinical Correlates of Human Immunodeficiency Virus-1 (HIV-1) DNA and Inducible HIV-1 RNA Reservoirs in Peripheral Blood in Children With Perinatally Acquired HIV-1 Infection With Sustained Virologic Suppression for at Least 5 Years.
Bitnun A, Ransy DG, Brophy J, Kakkar F, Hawkes M, Samson L, Annabi B, Pagliuzza A, Morand JA, Sauve L, Chomont N, Lavoie S, Kim J, Sandstrom P, Wender PA, Lee T, Singer J, Read SE, Soudeyns H; Early Pediatric Initiation Canada Child Cure Cohort (EPIC4) Research Group. Bitnun A, et al. Among authors: pagliuzza a. Clin Infect Dis. 2020 Feb 14;70(5):859-866. doi: 10.1093/cid/ciz251. Clin Infect Dis. 2020. PMID: 30919879 Free PMC article.
Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size.
Stone M, Rosenbloom DIS, Bacchetti P, Deng X, Dimapasoc M, Keating S, Bakkour S, Richman DD, Mellors JW, Deeks SG, Lai J, Beg S, Siliciano JD, Pagliuzza A, Chomont N, Lackman-Smith C, Ptak RG, Busch MP. Stone M, et al. Among authors: pagliuzza a. J Infect Dis. 2021 Oct 13;224(7):1209-1218. doi: 10.1093/infdis/jiaa089. J Infect Dis. 2021. PMID: 32147687 Free PMC article.
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.
Cale EM, Bai H, Bose M, Messina MA, Colby DJ, Sanders-Buell E, Dearlove B, Li Y, Engeman E, Silas D, O'Sullivan AM, Mann B, Pinyakorn S, Intasan J, Benjapornpong K, Sacdalan C, Kroon E, Phanuphak N, Gramzinski R, Vasan S, Robb ML, Michael NL, Lynch RM, Bailer RT, Pagliuzza A, Chomont N, Pegu A, Doria-Rose NA, Trautmann L, Crowell TA, Mascola JR, Ananworanich J, Tovanabutra S, Rolland M; RV397 Study Group. Cale EM, et al. Among authors: pagliuzza a. J Clin Invest. 2020 Jun 1;130(6):3299-3304. doi: 10.1172/JCI134395. J Clin Invest. 2020. PMID: 32182219 Free PMC article. Clinical Trial.
46 results